69 results
8-K
EX-99.1
ALNY
Alnylam Pharmaceuticals Inc
2 Nov 23
Results of Operations and Financial Condition
8:10am
at the Heart Failure Society of America Annual Scientific Meeting 2023.
Published results from Phase 3 APOLLO-B study of patisiran in the New England
8-K
EX-99.1
ALNY
Alnylam Pharmaceuticals Inc
10 Oct 23
Alnylam Announces Receipt of Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the
7:30am
of the ongoing open-label extension (OLE) period of the APOLLO-B Phase 3 study were presented at the Heart Failure Society of America (HFSA) Annual
8-K
EX-99.1
ALNY
Alnylam Pharmaceuticals Inc
4 May 23
Results of Operations and Financial Condition
8:10am
through Month 36 at the Hemostasis & Thrombosis Research Society (HTRS) Scientific Symposium.
Presented preclinical data for ALN-HTT, for the potential
8-K
EX-99.1
paye3
28 Oct 21
Alnylam Pharmaceuticals Reports Third Quarter 2021 Financial Results and Highlights Recent Period Activity
8:11am
8-K
EX-99.1
0lunhip37udrma j5t75
6 Feb 20
Results of Operations and Financial Condition
8:28am
8-K
EX-99.1
sarvi0 1u8696gx
31 Oct 19
Results of Operations and Financial Condition
8:10am
8-K
EX-99.1
uboj868qzya4mju y4
1 May 19
Alnylam Pharmaceuticals Reports First Quarter 2019 Financial Results and Highlights Recent Period Activity
8:45am
PRER14A
lu8thnp879s
18 Mar 19
Preliminary revised proxy
5:24pm
PRE 14A
l6u ys0ah
11 Mar 19
Preliminary proxy
5:07pm
8-K
EX-99.1
b1ru hkr6
7 Feb 19
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Recent Period Activity
4:15pm